Phase 2a Trial of CER-001 for Septic Patients and Future Biotech Meetings | Cyrille Tupin, CEO, Abionyx Pharma SA . 00:10:00

Share On Facebook Share On Twitter

The interview provides insights into recent data from a phase 2a pilot clinical trial assessing CER-001's efficacy in treating septic patients at high risk of acute renal failure, alongside a preview of upcoming biotech meetings.

Recent Videos